Julie Frearson, Ph.D. joined Charles River in 2014 and leads Charles River’s effort in developing and managing strategic technology partnerships, which are fundamental to the company’s continued growth and future market leadership. She also plays a key role in the evaluation of Charles River’s strategic acquisitions. Professor Frearson has substantial experience in early-stage drug discovery across multiple gene families and therapeutic areas as a result of roles with the Babraham Institute (Cambridge, UK), Zeneca UK, Cambridge Drug Discovery, BioFocus, and a tenured faculty position in the drug discovery unit of the University of Dundee. She has also served as director for the Scottish Universities Life Sciences Alliance (SULSA) and on the Medical Research Council and the Wellcome Trust expert committees. Prof. Frearson is author of more than 50 peer-reviewed publications. Prof. Frearson received a Ph.D. in biochemistry from King’s College London, University of London.